{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:50:43Z","timestamp":1759481443263,"version":"3.44.0"},"reference-count":46,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780128171431"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.acc.2018.10.003","type":"book-chapter","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T18:30:54Z","timestamp":1542393054000},"page":"151-167","source":"Crossref","is-referenced-by-count":9,"title":["Emicizumab (ACE910): Clinical background and laboratory assessment of hemophilia A"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.acc.2018.10.003_bb0010","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/07853890.2011.576698","article-title":"Inherited disorders of blood coagulation","volume":"44","author":"Lippi","year":"2012","journal-title":"Ann. Med."},{"key":"10.1016\/bs.acc.2018.10.003_bb0015","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1055\/s-0037-1612626","article-title":"Inhibitors in hemophilia: treatment challenges and novel options","volume":"44","author":"Barg","year":"2018","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/bs.acc.2018.10.003_bb0020","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.thromres.2016.10.024","article-title":"Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?","volume":"148","author":"Franchini","year":"2016","journal-title":"Thromb. Res."},{"key":"10.1016\/bs.acc.2018.10.003_bb0025","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1055\/s-0038-1666823","article-title":"Preventing or eradicating factor VIII antibody formation in patients with hemophilia A: what can we learn from other disorders?","volume":"44","author":"Hassan","year":"2018","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/bs.acc.2018.10.003_bb0030","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1055\/s-0038-1660817","article-title":"Inhibitors in hemophilia B","volume":"44","author":"Santoro","year":"2018","journal-title":"Semin. Thromb. Hemost."},{"year":"2016","series-title":"Report on the WFH Annual Global Survey","author":"World Federation of Hemophilia","key":"10.1016\/bs.acc.2018.10.003_bb0035"},{"key":"10.1016\/bs.acc.2018.10.003_bb0040","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.blre.2018.02.003","article-title":"Review of immune tolerance induction in hemophilia A","volume":"32","author":"Schep","year":"2018","journal-title":"Blood Rev."},{"key":"10.1016\/bs.acc.2018.10.003_bb0045","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1055\/s-0038-1657777","article-title":"Inhibitor formation in congenital hemophilia A: an immunological perspective","volume":"44","author":"Delignat","year":"2018","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/bs.acc.2018.10.003_bb0050","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1055\/s-0037-1612627","article-title":"Inhibitors in hemophilia A: a pharmacoeconomic perspective","volume":"44","author":"Messori","year":"2018","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/bs.acc.2018.10.003_bb0055","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-01-528414","article-title":"Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens","volume":"125","author":"Oldenburg","year":"2015","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2018.10.003_bb0060","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1055\/s-0036-1579637","article-title":"The future of hemophilia treatment: longer-acting factor concentrates versus gene therapy","volume":"42","author":"Giangrande","year":"2016","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/bs.acc.2018.10.003_bb0065","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1055\/s-0036-1571315","article-title":"Prophylaxis for hemophilia in the era of extended half-life factor VIII\/factor IX products","volume":"42","author":"Berntorp","year":"2016","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/bs.acc.2018.10.003_bb0070","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1055\/s-0038-1648230","article-title":"Treatment regimens with bypassing agents in patients with hemophilia A and inhibitors: a survey from the Italian Association of Hemophilia Centers (AICE)","volume":"44","author":"Coppola","year":"2018","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/bs.acc.2018.10.003_bb0075","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40265-018-0861-2","article-title":"Emicizumab-kxwh: first global approval","volume":"78","author":"Scott","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/bs.acc.2018.10.003_bb0080","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/bs.acc.2018.10.003_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057479","article-title":"Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity","volume":"8","author":"Sampei","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.acc.2018.10.003_bb0090","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/jth.12474","article-title":"Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation","volume":"12","author":"Muto","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2018.10.003_bb0095","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2014-07-585737","article-title":"Anti-factor IXa\/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A","volume":"124","author":"Muto","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2018.10.003_bb0100","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects","volume":"127","author":"Uchida","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2018.10.003_bb0105","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2018.10.003_bb0110","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2018.10.003_bb0115","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.acc.2018.10.003_bb0120","doi-asserted-by":"crossref","DOI":"10.1111\/jth.14203","article-title":"In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents","volume":"16","author":"Hartmann","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2018.10.003_bb0125","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s40262-017-0616-3","article-title":"A pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for emicizumab in hemophilia A","volume":"57","author":"Yoneyama","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/bs.acc.2018.10.003_bb0130","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/hae.13495","article-title":"Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving emicizumab. Interim guidance from UKHCDO inhibitor working party and executive committee","volume":"24","author":"Collins","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2018.10.003_bb0135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.21037\/atm.2017.02.34","article-title":"Emerging treatments for hemophilia: patients and their treaters spoilt for choice, but laboratories face a difficult path?","volume":"5","author":"Favaloro","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/bs.acc.2018.10.003_bb0140","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.transci.2018.05.020","article-title":"Usefulness of chromogenic assays for potency assignment and recovery of plasma-derived FVIII and FIX concentrates or their recombinant long acting therapeutic equivalents with potential application in treated pediatric hemophiliac patients","volume":"57","author":"Amiral","year":"2018","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/bs.acc.2018.10.003_bb0145","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/978-1-4939-7196-1_20","article-title":"One-stage factor VIII assays","volume":"1646","author":"Duncan","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/bs.acc.2018.10.003_bb0150","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/978-1-4939-7196-1_21","article-title":"Chromogenic factor VIII assays for improved diagnosis of hemophilia A","volume":"1646","author":"Rodgers","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/bs.acc.2018.10.003_bb0155","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/978-1-4939-7196-1_23","article-title":"Detection and measurement of factor inhibitors","volume":"1646","author":"Kershaw","year":"2017","journal-title":"Methods Mol. Biol."},{"author":"Medical and Scientific Advisory Committee","key":"10.1016\/bs.acc.2018.10.003_bb0160"},{"key":"10.1016\/bs.acc.2018.10.003_bb0165","first-page":"1080","article-title":"A bispecific antibody lacks measurability in routine coagulation assays and comparability to factor VIII","volume":"130","author":"Hartmann","year":"2017","journal-title":"Blood"},{"key":"10.1016\/bs.acc.2018.10.003_bb0170","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jth.14135","article-title":"Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies","volume":"16","author":"Nogami","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2018.10.003_bb0175","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.3324\/haematol.2017.185330","article-title":"Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab","volume":"103","author":"Dargaud","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/bs.acc.2018.10.003_bb0180","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/jth.14022","article-title":"Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa\/factor X bispecific antibody emicizumab","volume":"16","author":"Nogami","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/bs.acc.2018.10.003_bb0185","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1055\/s-0035-1546827","article-title":"Laboratory testing in the era of direct or non-vitamin K antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors","volume":"41","author":"Favaloro","year":"2015","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/bs.acc.2018.10.003_bb0190","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/atm.2017.01.03","article-title":"Laboratory monitoring of direct oral anticoagulants (DOACs)\u2014the perfect storm?","volume":"5","author":"Lippi","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/bs.acc.2018.10.003_bb0195","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.thromres.2010.04.004","article-title":"The \u201cnormal\u201d factor VIII concentration in plasma","volume":"126","author":"Butenas","year":"2010","journal-title":"Thromb. Res."},{"key":"10.1016\/bs.acc.2018.10.003_bb0200","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/hae.12872","article-title":"Activation, activity and inactivation of factor VIII in factor VIII products","volume":"22","author":"Orfeo","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/bs.acc.2018.10.003_bb0205","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1515\/cclm-2018-0174","article-title":"On the complexity of hemostasis and the need for harmonization of test practice","volume":"56","author":"Favaloro","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2018.10.003_bb0210","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1373\/clinchem.2015.248625","article-title":"Thrombin generation assay and its application in the clinical laboratory","volume":"62","author":"Tripodi","year":"2016","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2018.10.003_bb0215","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/bs.acc.2015.03.006","article-title":"Monitoring trastuzumab resistance and cardiotoxicity: a tale of personalized medicine","volume":"70","author":"Dokmanovic","year":"2015","journal-title":"Adv. Clin. Chem."},{"issue":"3","key":"10.1016\/bs.acc.2018.10.003_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22307","article-title":"Therapeutic monoclonal antibodies and clinical laboratory tests: when, why, and what is expected?","volume":"32","author":"Zhang","year":"2018","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/bs.acc.2018.10.003_bb0225","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1515\/cclm-2017-1205","article-title":"Laboratory hemostasis: from biology to the bench","volume":"56","author":"Lippi","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2018.10.003_bb0230","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"author":"BioPharm","key":"10.1016\/bs.acc.2018.10.003_bb0235"}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242318300556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242318300556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T19:37:28Z","timestamp":1758742648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242318300556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780128171431"],"references-count":46,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2018.10.003","relation":{},"ISSN":["0065-2423"],"issn-type":[{"type":"print","value":"0065-2423"}],"subject":[],"published":{"date-parts":[[2019]]}}}